- Investing Ideas
- Australian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Australian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
4
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
4 companies
CSL
Market Cap: AU$66.8b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$139.19
7D
0.2%
1Y
-40.3%
Telix Pharmaceuticals
Market Cap: AU$5.0b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$14.64
7D
13.1%
1Y
-44.1%
Mayne Pharma Group
Market Cap: AU$182.0m
A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYX
AU$2.24
7D
-3.9%
1Y
-67.9%
Vitura Health
Market Cap: AU$27.2m
Engages in the sale and distribution of medicinal cannabis products in Australia.
VIT
AU$0.041
7D
7.9%
1Y
-43.8%